• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺基底样Ⅲ级浸润性导管癌:转移模式与长期生存情况

Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival.

作者信息

Fulford Laura G, Reis-Filho Jorge S, Ryder Ken, Jones Chris, Gillett Cheryl E, Hanby Andrew, Easton Douglas, Lakhani Sunil R

机构信息

Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London, SW3 6JB, UK.

出版信息

Breast Cancer Res. 2007;9(1):R4. doi: 10.1186/bcr1636.

DOI:10.1186/bcr1636
PMID:17217540
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1851397/
Abstract

INTRODUCTION

Cytokeratin (CK) 14, one of several markers expressed in normal myoepithelial/basal cells, is also expressed in a proportion of breast carcinomas. Previous studies have suggested that expression of such 'basal' markers predicts different biological behaviour, with more frequent lung and brain metastases and poorer prognosis than other carcinomas.

METHODS

We performed CK14 immunohistochemistry on 443 grade III invasive ductal carcinomas with extended clinical follow-up (mean 116 months), and we correlated CK14 immunopositivity (basal-like phenotype) with clinicopathological criteria.

RESULTS

Eighty-eight of 443 (20%) tumours showed CK14 expression. CK14-positive tumours were more likely to be oestrogen receptor-negative (p < 0.0001) and axillary node-negative (p = 0.001) than were CK14-negative cases. CK14-positive cases developed less bone and liver metastases (hazard ratio [HR] 0.49, p = 0.01, and HR 0.53, p = 0.035, respectively) but more frequent brain metastases (HR 1.92, p = 0.051). In patients without metastatic disease, disease-free survival in CK14-positive cases was significantly better than in CK14-negative cases (HR 0.65, p = 0.005). In patients with metastatic disease, however, CK14 positivity was associated with a poorer prognosis (HR 1.84, p = 0.001). The overall survival in CK14-positive and -negative patients was similar at 5 years (60% and 59%, respectively), but the long-term survival was better in CK14-positive patients (HR 0.69, p = 0.02).

CONCLUSION

These results demonstrate that basal-like tumours differ in their biological behaviour from other tumours, with a distinct pattern of metastatic spread. Compared to other grade III tumours, basal-like tumours appear to have a relatively good long-term survival but survival after metastases is poor.

摘要

引言

细胞角蛋白(CK)14是在正常肌上皮/基底细胞中表达的几种标志物之一,在一部分乳腺癌中也有表达。先前的研究表明,此类“基底”标志物的表达预示着不同的生物学行为,与其他类型的癌相比,发生肺转移和脑转移更为频繁,预后更差。

方法

我们对443例III级浸润性导管癌进行了CK14免疫组化检测,并进行了延长的临床随访(平均116个月),我们将CK14免疫阳性(基底样表型)与临床病理标准进行了关联分析。

结果

443例肿瘤中有88例(20%)显示CK14表达。与CK14阴性病例相比,CK14阳性肿瘤更可能为雌激素受体阴性(p < 0.0001)和腋窝淋巴结阴性(p = 0.001)。CK14阳性病例发生骨转移和肝转移较少(风险比[HR]分别为0.49,p = 0.01和HR 0.53,p = 0.035),但脑转移更为频繁(HR 1.92,p = 0.051)。在无转移性疾病的患者中,CK14阳性病例的无病生存期明显优于CK14阴性病例(HR 0.65,p = 0.005)。然而,在有转移性疾病的患者中,CK14阳性与较差的预后相关(HR 1.84,p = 0.001)。CK14阳性和阴性患者的5年总生存率相似(分别为60%和59%),但CK14阳性患者的长期生存率更好(HR 0.69,p = 0.02)。

结论

这些结果表明,基底样肿瘤的生物学行为与其他肿瘤不同,具有独特的转移扩散模式。与其他III级肿瘤相比,基底样肿瘤似乎具有相对较好的长期生存率,但发生转移后的生存率较差。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bff/1851397/775916b5b910/bcr1636-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bff/1851397/5e52583b803e/bcr1636-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bff/1851397/775916b5b910/bcr1636-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bff/1851397/5e52583b803e/bcr1636-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7bff/1851397/775916b5b910/bcr1636-2.jpg

相似文献

1
Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival.乳腺基底样Ⅲ级浸润性导管癌:转移模式与长期生存情况
Breast Cancer Res. 2007;9(1):R4. doi: 10.1186/bcr1636.
2
Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.具有基底和肌上皮分化的乳腺癌的形态学和免疫表型分析
J Pathol. 2006 Mar;208(4):495-506. doi: 10.1002/path.1916.
3
BRCA-mutated Invasive Breast Carcinomas: Immunohistochemical Analysis of Insulin-like Growth Factor II mRNA-binding Protein (IMP3), Cytokeratin 8/18, and Cytokeratin 14.BRCA 突变的浸润性乳腺癌:胰岛素样生长因子 II mRNA 结合蛋白(IMP3)、细胞角蛋白 8/18 和细胞角蛋白 14 的免疫组织化学分析
Breast J. 2015 Nov-Dec;21(6):596-603. doi: 10.1111/tbj.12494. Epub 2015 Sep 22.
4
[Clinicopathologic study of centrally necrotizing carcinoma of breast].[乳腺中心坏死性癌的临床病理研究]
Zhonghua Bing Li Xue Za Zhi. 2009 Oct;38(10):657-62.
5
Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer.Maspin 表达在三阴性乳腺癌中较为常见,并与基底标志物相关。
Diagn Pathol. 2011 Apr 16;6:36. doi: 10.1186/1746-1596-6-36.
6
Cytokeratin profiles of male breast cancers.男性乳腺癌的细胞角蛋白谱
Histopathology. 2006 Oct;49(4):365-70. doi: 10.1111/j.1365-2559.2006.02519.x.
7
[Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].[免疫组织化学在基底样乳腺癌预后评估中的作用]
Zhonghua Bing Li Xue Za Zhi. 2009 Jan;38(1):23-8.
8
[Basal and myoepithelial phenotype of metastatic mammary carcinomas. A prognostic factor in the palliative situation?].[转移性乳腺癌的基底和肌上皮表型。在姑息治疗情况下是一个预后因素吗?]
Pathologe. 2008 Nov;29 Suppl 2:363-9. doi: 10.1007/s00292-008-1032-0.
9
CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation.伴有基底样/肌上皮细胞分化的乳腺导管癌的比较基因组杂交分析
Br J Cancer. 2001 Aug 3;85(3):422-7. doi: 10.1054/bjoc.2001.1869.
10
Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes.具有不同临床结局的III级浸润性导管癌亚组的分子细胞遗传学鉴定
Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):5988-97. doi: 10.1158/1078-0432.CCR-03-0731.

引用本文的文献

1
Role of PARP Inhibitors: A New Hope for Breast Cancer Therapy.聚(ADP-核糖)聚合酶(PARP)抑制剂的作用:乳腺癌治疗的新希望。
Int J Mol Sci. 2025 Mar 19;26(6):2773. doi: 10.3390/ijms26062773.
2
Prognosis model of patients with breast cancer based on metabolism-related LncRNAs.基于代谢相关长链非编码RNA的乳腺癌患者预后模型
Discov Oncol. 2025 Mar 25;16(1):390. doi: 10.1007/s12672-025-02178-y.
3
The m6A demethylase FTO promotes C/EBPβ-LIP translation to perform oncogenic functions in breast cancer cells.m6A去甲基化酶FTO促进C/EBPβ-LIP的翻译,从而在乳腺癌细胞中发挥致癌功能。

本文引用的文献

1
BRCA1 dysfunction in sporadic basal-like breast cancer.散发性基底样乳腺癌中的BRCA1功能障碍。
Oncogene. 2007 Mar 29;26(14):2126-32. doi: 10.1038/sj.onc.1210014. Epub 2006 Oct 2.
2
Basal-like breast cancer and the BRCA1 phenotype.基底样乳腺癌与BRCA1表型
Oncogene. 2006 Sep 25;25(43):5846-53. doi: 10.1038/sj.onc.1209876.
3
Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.乳腺癌基底样亚型的临床病理意义:与激素受体及Her2/neu过表达表型的比较
FEBS J. 2025 May;292(10):2688-2709. doi: 10.1111/febs.70033. Epub 2025 Feb 28.
4
Prognostic Value of "Basal-like" Morphology, Tumor-Infiltrating Lymphocytes and Multi-MAGE-A Expression in Triple-Negative Breast Cancer.“基底样”形态、肿瘤浸润淋巴细胞及多MAGE-A表达在三阴性乳腺癌中的预后价值
Int J Mol Sci. 2024 Apr 20;25(8):4513. doi: 10.3390/ijms25084513.
5
A genetic mosaic mouse model illuminates the pre-malignant progression of basal-like breast cancer.遗传嵌合体小鼠模型阐明了基底样乳腺癌的恶性前进展。
Dis Model Mech. 2023 Nov 1;16(11). doi: 10.1242/dmm.050219. Epub 2023 Nov 13.
6
Targeting Triple-Negative Breast Cancer by the Phytopolyphenol Carnosol: ROS-Dependent Mechanisms.植物多酚鼠尾草酸靶向三阴性乳腺癌:依赖活性氧的机制
Antioxidants (Basel). 2023 Jun 27;12(7):1349. doi: 10.3390/antiox12071349.
7
Bioinformatics driven discovery of small molecule compounds that modulate the FOXM1 and PPARA pathway activities in breast cancer.基于生物信息学的发现,小分子化合物可调节乳腺癌中 FOXM1 和 PPARA 通路的活性。
Pharmacogenomics J. 2023 Jul;23(4):61-72. doi: 10.1038/s41397-022-00297-1. Epub 2022 Nov 24.
8
Hypoxia Triggers TAZ Phosphorylation in Basal A Triple Negative Breast Cancer Cells.缺氧在基底型三阴性乳腺癌细胞中触发 TAZ 磷酸化。
Int J Mol Sci. 2022 Sep 4;23(17):10119. doi: 10.3390/ijms231710119.
9
Importance of tumor subtypes in cancer imaging.肿瘤亚型在癌症成像中的重要性。
Eur J Radiol Open. 2022 Jul 26;9:100433. doi: 10.1016/j.ejro.2022.100433. eCollection 2022.
10
A Novel Risk-Scoring System to Identify the Potential Population Benefiting From Adjuvant Chemotherapy for Node-Negative TNBC Patients With Tumor Size Less Than 1 cm.一种新型风险评分系统,用于识别肿瘤大小小于1cm的淋巴结阴性三阴性乳腺癌患者中可能从辅助化疗中获益的人群。
Front Oncol. 2022 Jun 23;12:788883. doi: 10.3389/fonc.2022.788883. eCollection 2022.
Hum Pathol. 2006 Sep;37(9):1217-26. doi: 10.1016/j.humpath.2006.04.015. Epub 2006 Jul 18.
4
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.发生脑转移的乳腺癌更有可能雌激素受体阴性,表达基底细胞角蛋白CK5/6,并过度表达HER2或EGFR。
Am J Surg Pathol. 2006 Sep;30(9):1097-104. doi: 10.1097/01.pas.0000213306.05811.b9.
5
Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer.基底腔内癌:一种在基底型和腔面型乳腺癌之间新的生物学和预后上截然不同的实体。
Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4185-91. doi: 10.1158/1078-0432.CCR-06-0353.
6
Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast.预测乳腺浸润性导管癌3级基底样表型的特异性形态学特征。
Histopathology. 2006 Jul;49(1):22-34. doi: 10.1111/j.1365-2559.2006.02453.x.
7
Metaplastic breast carcinomas are basal-like tumours.化生性乳腺癌是基底样肿瘤。
Histopathology. 2006 Jul;49(1):10-21. doi: 10.1111/j.1365-2559.2006.02467.x.
8
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.《卡罗来纳乳腺癌研究中的种族、乳腺癌亚型与生存率》
JAMA. 2006 Jun 7;295(21):2492-502. doi: 10.1001/jama.295.21.2492.
9
Basal-like breast carcinomas: clinical outcome and response to chemotherapy.基底样乳腺癌:临床结局及对化疗的反应
J Clin Pathol. 2006 Jul;59(7):729-35. doi: 10.1136/jcp.2005.033043. Epub 2006 Mar 23.
10
Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.具有基底和肌上皮分化的乳腺癌的形态学和免疫表型分析
J Pathol. 2006 Mar;208(4):495-506. doi: 10.1002/path.1916.